• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Sorafenib increases progression-free survival in patients with desmoid tumors

byDayton McMillan
December 25, 2018
in Chronic Disease, Oncology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. After 2 years of treatment with sorafenib, patients with desmoid tumors had significantly increased progression-free survival rates compared to patients randomized to a placebo treatment.

2. Adverse effects most commonly reported by patients in the sorafenib group included rash and fatigue.

Evidence Rating Level: 1 (Excellent)      

Study Rundown: Desmoid tumors, also known as aggressive fibromatosis, are rare connective tissue neoplasms with no standard systemic treatment. While the tumors do no metastasize, patients may experience both symptoms and possibly increased mortality due to local growth and tissue invasion. While local surgery or radiation may be utilized, recurrence after treatment does occur. A prior study showed potential benefit to patients with treatment using the tyrosine kinase inhibitor sorafenib, prompting this study to further evaluate the efficacy and safety of this treatment for patients with desmoid tumors. Patients randomized to treatment with sorafenib experienced an increased 2-year progression-free survival rate, the primary outcome, compared to those treated with placebo. Most patients in the sorafenib group experienced adverse events, with the most common being rash and fatigue.

This study further evaluated a promising treatment strategy for patients with desmoid tumors, a diagnosis presently without a standard systemic therapy. Strengths of the study include its randomized design, follow-up with imaging, and extensive adverse event monitoring. Limitations include limited enrollment partially due to the rare nature of the disease, poor definition of objective response, and immaturity of survival and crossover data.

Click to read the study in NEJM

RELATED REPORTS

Nivolumab plus ipilimumab improves survival over lenvatinib or sorafenib in liver cancer

Camrelizumab plus rivoceranib superior to sorafenib for treatment of unresectable hepatocellular carcinoma

Adjuvant everolimus does not improve survival for patients with resected renal cell carcinoma

Relevant Reading: Desmoid tumors: a review of their natural history, imaging, and treatment 

In-Depth [randomized controlled trial]: This phase 3, multicenter, randomized, placebo-controlled trial enrolled patients between 2014 and 2016. Eligible patients had a diagnosis of desmoid tumor and radiographic progression of disease within the prior 6 months, recurrence after local treatment, or symptomatic disease. Patients were randomized in a 2:1 ratio to sorafenib (n=50) or placebo (n=37) groups, and patients were followed for a median of 27.2 months. The primary endpoint, progression-free survival at 2 years, was 81% in the sorafenib group and 36% in the placebo group (hazard ratio for disease progression or death, 0.13; 95% confidence interval [CI], 0.05 to 0.31; P<0.001). Objective response, defined with imaging performed every 8 weeks during trial enrollment, occurred in 33% of the treatment group and 20% of the placebo group. For patients who showed a response on imaging, the mean time to response was 9.6 months in the treatment group and 13.3 months in the placebo group. For the 85 patients with adverse response data, grade 3 or 4 adverse events occurred in 47% (23/49) of those in the treatment group and in 25% (9/36) of the placebo group. The most common grade 1 or 2 adverse events in the treatment group included rash (73%) and fatigue (67%).

Image: PD

©2018 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc

Tags: desmoid tumorsorafenibtyrosine kinase inhibitor
Previous Post

Risk of lifetime stroke exhibits notable geographic variation

Next Post

Hospital Readmissions Reduction Program associated with increased 30-day post-discharge mortality for heart failure and pneumonia                                                      

RelatedReports

Prognostic indicators for transarterial chemoembolization in patients with hepatocellular carcinoma with extrahepatic spread identified
AI Roundup

Nivolumab plus ipilimumab improves survival over lenvatinib or sorafenib in liver cancer

June 12, 2025
Prognostic nomograms predict survival after chemoembolization of hepatocellular carcinoma
Chronic Disease

Camrelizumab plus rivoceranib superior to sorafenib for treatment of unresectable hepatocellular carcinoma

October 11, 2023
Pediatric renal and thyroid cancer rates increase
Chronic Disease

Adjuvant everolimus does not improve survival for patients with resected renal cell carcinoma

October 10, 2023
#VisualAbstract Ponatinib with FLAG-IDA is a feasible and active treatment strategy in patients with blast-phase chronic myeloid leukaemia
StudyGraphics

#VisualAbstract Ponatinib with FLAG-IDA is a feasible and active treatment strategy in patients with blast-phase chronic myeloid leukaemia

June 12, 2022
Next Post
Treatment of subclinical hypothyroidism ineffective in older adults

Hospital Readmissions Reduction Program associated with increased 30-day post-discharge mortality for heart failure and pneumonia                                                      

Many new pediatric asthma cases attributable to obesity

Genetic variants of increased waist-to-hip ratios associated with diabetes and coronary disease

#VisualAbstract: Effect of Oral Alfacalcidol on Clinical Outcomes in Patients Without Secondary Hyperparathyroidism Receiving Maintenance Hemodialysis

#VisualAbstract: Effect of Oral Alfacalcidol on Clinical Outcomes in Patients Without Secondary Hyperparathyroidism Receiving Maintenance Hemodialysis

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Transcatheter closure of patent ductus arteriosus demonstrates similar outcomes compared to surgical repair
  • #VisualAbstract: Encorafenib, Cetuximab, and mFOLFOX6 Improves Survival in BRAF-Mutated Colorectal Cancer
  • Use of psychiatric medications may be associated with a higher risk of amyotrophic lateral sclerosis
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.